Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells

被引:60
|
作者
Yeung, F
Li, XY
Ellett, J
Trapman, J
Kao, CH
Chung, LWK [1 ]
机构
[1] Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA
[2] Univ Virginia, Dept Urol, Charlottesville, VA 22908 USA
[3] Erasmus Univ, Dept Pathol, NL-3000 DR Rotterdam, Netherlands
[4] Indiana Canc Pavil, Dept Urol, Indianapolis, IN 46202 USA
关键词
D O I
10.1074/jbc.M002755200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostate-specific antigen (PSA) is expressed primarily by both normal prostate epithelium and the vast majority of prostate cancers. Increases in serum PSA during endocrine therapy are generally considered as evidence for prostate cancer recurrence or progression to androgen independence. The mechanisms by which PSA upregulation occurs in androgen-refractory prostate cancer cells are unknown. In this study, by using LNCaP and its lineage-derived androgen-independent PSA-producing subline, C4-2, we identified two cis-elements within the 5.8-bilobase pair PSA promoter that are essential for the androgen-independent activity of PSA promoter in prostate cancer cells. First, a previously reported 440-bp androgen-responsive Element enhancer core (AREc) was found to be important for the high basal PSA promoter activity in C4-2 cells. Both mutation analysis and supershift experiments demonstrated that androgen receptor (AR) binds to the AREs within the AREc and activate the basal PSA promoter activity in C4-2 cells under androgen-deprived conditions. Second, a 150-bp pN/H region was demonstrated to be a strong AR-independent positive-regulatory element of the PSA promoter in both LNCaP and C4-2 cells. Through DNase I footprinting and linker scan mutagenesis, a 17-bp RI site was identified as the key cis-element within the pN/H region. Data from electrophoretic mobility shift analysis and UV cross-linking experiments further indicated that a 45-kDa (p45) cell-specific transcription factor associates with RI in prostate cancer cells and may be responsible for driving the PSA promoter activity independent of androgen and AR. Furthermore, by juxtaposing AREc and pN/H, we produced a chimeric PSA promoter (supra-PSA) that exhibits 2-3-fold higher activity than the wild type PSA promoter in both LNCaP and C4-2 cells.
引用
收藏
页码:40846 / 40855
页数:10
相关论文
共 50 条
  • [21] Prostate-specific antigen (PSA): A tumor marker in the diagnosis of prostate cancer
    Ohlendorf D.
    Wanke E.M.
    Braun M.
    Oremek G.M.
    Groneberg D.A.
    Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, 2017, 67 (4) : 221 - 223
  • [22] Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells
    Blaszczyk, N
    Masri, BA
    Mawji, NR
    Ueda, T
    McAlinden, G
    Duncan, CP
    Bruchovsky, N
    Schweikert, HU
    Schnabel, D
    Jones, EC
    Sadar, MD
    CLINICAL CANCER RESEARCH, 2004, 10 (05) : 1860 - 1869
  • [23] Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer
    Tobias Nordström
    Olof Akre
    Markus Aly
    Henrik Grönberg
    Martin Eklund
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 57 - 63
  • [24] Anti-PSA MAbs and prostate-specific antigen (PSA)
    Chou, SF
    HYBRIDOMA AND HYBRIDOMICS, 2004, 23 (02): : 150 - 150
  • [25] Docetaxel Down-Regulates the Expression of Androgen Receptor and Prostate-Specific Antigen But Not Prostate-Specific Membrane Antigen in Prostate Cancer Cell Lines: Implications for PSA Surrogacy
    Kuroda, Kenji
    Liu, He
    Kim, Sae
    Guo, Ming
    Navarro, Vincent
    Bander, Neil H.
    PROSTATE, 2009, 69 (14): : 1579 - 1585
  • [26] Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time
    Ng, Michael K.
    Van As, Nicholas
    Thomas, Karen
    Woode-Amissah, Ruth
    Horwich, Alan
    Huddart, Robert
    Khoo, Vincent
    Thompson, Alan
    Dearnaley, David
    Parker, Chris
    BJU INTERNATIONAL, 2009, 103 (07) : 872 - 876
  • [27] Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer
    Morote, J
    Esquena, S
    Abascal, JM
    Trilla, E
    Cecchini, L
    Raventós, CX
    Orsola, A
    Planas, J
    Catalán, R
    Reventós, J
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2005, 20 (04): : 209 - 216
  • [28] Prostate cancer and prostate-specific antigen (PSA) screening in AustriaProstatakarzinom und PSA-Screening in Österreich
    Christian Vutuc
    Eva S. Schernhammer
    Gerald Haidinger
    Thomas Waldhör
    Wiener klinische Wochenschrift, 2005, 117 : 457 - 461
  • [29] Clinical evaluation of free PSA total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer
    Filella, X
    Alcover, J
    Molina, R
    Rodriguez, A
    Carretero, P
    Ballesta, AM
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (08) : 1226 - 1229
  • [30] Novel polymorphisms of prostate-specific antigen (PSA) gene associated with PSA mRNA expression in breast cancer
    Q.-F. Yang
    T. Sakurai
    L. Shan
    Z. Yu
    G. Yoshimura
    T. Suzuma
    T. Tamaki
    T. Umemura
    M. Nakamura
    Y. Nakamura
    I. Mori
    K. Kakudo
    Journal of Human Genetics, 2000, 45 : 363 - 366